Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

753.12
-9.6900-1.27%
Post-market: 753.120.00000.00%16:57 EDT
Volume:629.52K
Turnover:474.21M
Market Cap:77.54B
PE:18.63
High:765.60
Open:762.49
Low:743.57
Close:762.81
52wk High:859.34
52wk Low:553.87
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.11
T/O Rate:0.64%
Dividend:3.64
Dividend Rate:0.48%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.45
PE(LYR):18.16

Loading ...

Oct 06, 2026

Major Issues Report

Form 8-K - Current report
Sep 30, 2026

Major Issues Report

Form 8-K - Current report
Sep 04, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 03, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 03, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 10, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 10, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 30, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 30, 2026

Major Issues Report

Form 8-K - Current report
Jul 06, 2026

Major Issues Report

Form 8-K - Current report
Jul 02, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 18, 2026

Major Issues Report

Form 8-K - Current report
Apr 30, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Apr 29, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 29, 2026

Major Issues Report

Form 8-K - Current report
Apr 08, 2026

Major Issues Report

Form 8-K - Current report
Feb 19, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 09, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 09, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 04, 2026

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]